GlassScriptPhysician profile
Amy D Morgan
NPI 1396254488
$3,034.44
in general payments reported to CMS, 2019-2025
25 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $746 · 2022: $793 · 2023: $750 · 2024: $371 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449 · Education: $46.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.92 |
| Education | $46.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $682.42 | 2021-2025 | |
| Lilly USA, LLC | $613.84 | 2021-2025 | Verzenio, Retevmo, Jaypirca |
| Eisai INC. | $578.42 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $198.44 | 2021-2024 | Keytruda, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $144.01 | 2021-2023 | Imbruvica |
| Janssen Biotech, INC. | $138.31 | 2022-2024 | Imbruvica, Rybrevant |
| Karyopharm Therapeutics INC. | $128.24 | 2021-2024 | Xpovio |
| Genentech USA, INC. | $67.44 | 2021-2023 | Perjeta, Phesgo, Kadcyla |
| Astellas Pharma US INC | $64.99 | 2021 | |
| Glaxosmithkline, LLC. | $43.07 | 2025 | Zejula, Jemperli, Bexsero |
| Beigene USA, INC. | $42.09 | 2022-2024 | Tevimbra |
| Sun Pharmaceutical Industries INC. | $41.84 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $34.40 | 2021-2024 | Somatuline Depot, Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.98 | 2024 | Gilotrif |
| Janssen Scientific Affairs, LLC | $31.58 | 2025 | Tecvayli, Talvey, Carvykti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $27.66 | 2025 | Tevimbra |
| Myovant Sciences INC. | $26.65 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $21.16 | 2025 | |
| Novo Nordisk INC | $21.05 | 2022 | |
| Pfizer INC. | $18.07 | 2022 | |
| Iovance Biotherapeutics, INC. | $17.86 | 2025 | Amtagvi |
| Amneal Pharmaceuticals LLC | $17.37 | 2024 | Avastin |
| Exact Sciences Corporation | $16.82 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $13.37 | 2022 | |
| Sumitomo Pharma America, INC. | $13.36 | 2023 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.